Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp. > CEO JAMES PASSIN EVERYBODY KNOWS BIOV IN BED WITH TRACESAFE
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Comment by moneywagonon Nov 18, 2021 1:29pm
135 Views
Post# 34141733

RE:RE:RE:RE:CEO JAMES PASSIN EVERYBODY KNOWS BIOV IN BED WITH TRACESAFE

RE:RE:RE:RE:CEO JAMES PASSIN EVERYBODY KNOWS BIOV IN BED WITH TRACESAFENOPE NOT a single worry in the world about MM!!! all capital letters. CSE regulators and board members do not give a fying shyte about the stock forum sandbox bb's. lmfaso
Have you never seen the HUMONGOUS white crime that is executed on these penny stocks by insiders????
Now that is something CSE should look at!
Everyday for decades white crime is everywhere on these penny stocks, so posting insider leaks news ahead of retail is OLE OLE NEWS.
OMG how old are you?? The last thing you need to worry about, are bb posts, they not only NOT move the needle ever on an sp BUT BUTT what's so funny in your post ...........you actually think MM gives a flying shyte about wats posted. hahhaha oh the tears of laughter gut wrenching funny!
Hang in tiger sp is going down! yummy yum!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities